We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Momenta Must Face Clot Drug Antitrust Row, 1st Circ. Told

Law360, New York (November 1, 2016, 3:23 PM EDT) -- Misconduct by Momenta before a standard-setting organization that unknowingly led the group to create a standard for a blood-clot drug that requires the use of a company patent should not allow the generics maker to subsequently receive immunity from antitrust claims, generic rival Amphastar told the First Circuit on Monday.

The District of Massachusetts erred by holding in July that the so-called Noerr-Pennington doctrine allowed Momenta Pharmaceuticals Inc. and co-defendant Sandoz Inc. to escape the antitrust claims brought by Amphastar Pharmaceuticals Inc., which alleged that Momenta...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.